Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Burning Rock Biotech (BNR) Current Taxes (2021 - 2022)

Burning Rock Biotech has reported Current Taxes over the past 2 years, most recently at $208.6 million for Q2 2022.

For Q2 2022, Current Taxes changed N/A year-over-year to $208.6 million; the TTM value through Jun 2022 reached $208.6 million, changed N/A, while the annual FY2021 figure was $139.2 million, N/A changed from the prior year.
Current Taxes for Q2 2022 was $208.6 million at Burning Rock Biotech, up from $140.4 million in the prior quarter.
Over five years, Current Taxes peaked at $208.6 million in Q2 2022 and troughed at $140.4 million in Q4 2021.